GHRP-6

Introduction

GHRP-6 is a synthetic hexapeptide growth-hormone-releasing peptide developed alongside GHRP-2. Structurally similar to GHRP-2 but produces more pronounced appetite stimulation via the ghrelin pathway. Investigational; no approved indication in the United States.

Mechanism of Action

Agonist at the growth-hormone-secretagogue receptor (GHS-R1a). Receptor activation drives pulsatile GH release from anterior-pituitary somatotrophs and stimulates orexigenic centers in the hypothalamus.

Research Indications

Research overlaps with GHRP-2: GH-deficiency diagnostics, sarcopenia, cachexia, and recovery. The pronounced appetite effect makes GHRP-6 a candidate in cachexia and anorexia-of-aging contexts where weight gain is therapeutic.

Reconstitution

Typical 5 mg lyophilized vial: add 2 mL of bacteriostatic water, swirl gently. Final concentration 2500 mcg/mL (2.5 mg/mL) — each 0.04 mL (4 units on a U-100 insulin syringe) delivers 100 mcg.

Dosing Protocol (research literature)

Research protocols typically dose 100–300 mcg subcutaneously 1–3 times daily, with the largest pulse pre-sleep. Common pairing with sermorelin or CJC-1295 (no DAC) at 100 mcg each, pre-sleep on empty stomach. Cycle length 8–12 weeks with a 4-week off period before re-cycling.

Administration

Subcutaneous into abdominal fat, rotating sites. Dose on empty stomach; pre-sleep dose 60–90 minutes after last food. The hunger effect peaks 30–60 minutes after injection.

Storage & Handling

Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately 21–28 days. Protect from light.

Side Effects

Hunger (substantially more pronounced than GHRP-2), flushing, mild injection-site reaction, transient cortisol and prolactin elevation. Mild fluid retention at higher exposures.

Contraindications

Active malignancy, untreated proliferative diabetic retinopathy, pregnancy, lactation, uncontrolled diabetes, and any condition where appetite stimulation is undesirable.

Monitoring

Baseline IGF-1, fasting glucose, HbA1c, lipid panel; body weight and waist circumference for caloric-intake-relevant protocols. Re-measure IGF-1 at 6–8 weeks; reduce dose if trough IGF-1 exceeds the age-adjusted reference range.

Disclaimer

This article is for informational and research-reference purposes only. Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation.

Customers should do their own research and consult their own physician before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make.

The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.